One of the biggest challenges of covering the coronavirus/COVID-19 pandemic has been the proliferation of inaccurate information. That includes misinformation, propaganda, disinformation, conspiracy theories and, most pernicious of all, fake cures and treatments.
Some of the misinformation about substances that supposedly can treat COVID-19 is downright harmful, such as bleach or colloidal silver. The problem is so bad that the U.S Food and Drug Administration began issuing warning letters to multiple companies in early March to stop selling products that they said were fraudulently claiming could be used against coronavirus infections. Continue reading
Millions of people around the world take acid suppressants called proton pump inhibitors (PPIs) for conditions like heartburn, gastritis and stomach ulcers. Researchers at Karolinska Institutet in Sweden now report that long-term use of these drugs could increase the risk of developing dementia. Continue reading
Joyce Frieden, Washington editor at MedPage Today, and Keren Landman, M.D., a freelance journalist based in Atlanta, join four incumbents in being seated on the Association of Health Care Journalists’ 2020-21 board of directors.
Incumbents starting a new term include Carrie Feibel, senior editor of the Science Desk at NPR; Tony Leys, health care reporter at the Des Moines Register; Ivan Oransky, M.D., vice president of editorial for Medscape; and Sabriya Rice, Knight chair in health and medical journalism at the University of Georgia.
One of the most challenging aspects about reporting on medical research is the need to convey risk in a meaningful way to readers. Human brains are not wired to understand risk in the way we need to understand it in the 21st century. Our brains evolved to assess risks for very different environments and threats than those we face today ― particularly in a time of pandemic. Continue reading
Photo: ChiralJon via FlickrRendering of hydroxychloroquine molecular structure.
The National Institutes of Health last month halted a clinical trial of hydroxychloroquine for use in treating COVID-19 patients. The NIH ended the trial because the antimalarial drug, while safe, was proven to have no benefit to hospitalized patients.
The decision came just three months after President Trump declared the drug a “game-changer” and arranged for the U.S. to purchase 29 million doses to be “immediately available” to the public for treating the SARS-CoV-2 virus, which causes COVID-19. Continue reading
If you cover medical studies for national publications, you rarely have to worry about localizing it to one particular region. But local and state journalists typically have to go deeper when covering a national study for region-specific publications. A new obesity prevalence study is out? How does that compare to obesity rates in your state? In your county? In your city? In your schools? Continue reading